You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

NIFURTIMOX - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for nifurtimox and what is the scope of patent protection?

Nifurtimox is the generic ingredient in one branded drug marketed by Bayer Healthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for NIFURTIMOX
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 39
Clinical Trials: 22
Patent Applications: 10
What excipients (inactive ingredients) are in NIFURTIMOX?NIFURTIMOX excipients list
DailyMed Link:NIFURTIMOX at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NIFURTIMOX
Generic Entry Date for NIFURTIMOX*:
Constraining patent/regulatory exclusivity:
INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NIFURTIMOX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Juan D. MayaPhase 2
Laboratorio Elea Phoenix S.A.Phase 3
Drugs for Neglected Diseases initiativePhase 3

See all NIFURTIMOX clinical trials

US Patents and Regulatory Information for NIFURTIMOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-001 Aug 6, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-002 Aug 6, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-001 Aug 6, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-002 Aug 6, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.